Vinson & Elkins advised Lexicon Pharmaceuticals, while Simpson Thacher represented Invus on the deal. Cooley represented the underwriters for the public offering.Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Leila Ahmed
…
This content is for Standard 1 Year members only. LoginJoin Now